ReviewCells2022
Hereditary Ovarian Carcinoma: Cancer Pathogenesis Looking beyond
Review in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.
- Mirvetuximab Soravtansine in the Treatment of Chemotherapy-Resistant Ovarian Cancer: A Systematic Review.International journal of molecular sciences · 2026Pooled it
- Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature.Frontiers in oncology · 2022Pooled it
- The central precocious puberty-associated gene MKRN3 is a tumor suppressor regulating CSDE1 ubiquitination in ovarian cancer.Oncogenesis · 2026Article
- Targeting the JAK/STAT pathway with isoliquiritigenin in ovarian cancer: molecular mechanisms and therapeutic implications.Frontiers in pharmacology · 2026Review
- Prognostic and therapeutic implications of BRCA1 and BRCA2 mutations in ovarian cancer.Frontiers in oncology · 2026Review
- Feasibility of Trastuzumab-Deruxtecan in the Treatment of Ovarian Cancer: A Systematic Review.Journal of clinical medicine · 2025Review
- Identification and Computational Analysis ofMedical sciences (Basel, Switzerland) · 2025Article
- BRCA1 expression in ovarian cancer and its relationship with clinicopathological characteristics and prognosis.Scientific reports · 2025Article
- Role of DNA methylation and non‑coding RNAs expression in pathogenesis, detection, prognosis, and therapy‑resistant ovarian carcinoma (Review).Molecular medicine reports · 2025Review
- Article
- Olaparib promotes FABP4 expression and reduces antitumor effect in ovarian cancer cells with aOncology letters · 2025Article
- NGR-modified nanovesicles target ALKBH5 to inhibit ovarian cancer growth and metastasis.Theranostics · 2025Article
- Serous Tubal Intraepithelial Carcinoma (STIC): A Review of the Literature on the Incidence at the Time of Prophylactic Surgery.Diagnostics (Basel, Switzerland) · 2024Review
- RNA-binding protein THUMPD2 inhibits proliferation and promotes metastasis in epithelial ovarian cancer.Heliyon · 2024Article
- Targeting Neoantigens in Cancer: Possibilities and Opportunities in Breast Cancer.Antibodies (Basel, Switzerland) · 2024Review
- Involvement of Protease-Activated Receptor2 Pleckstrin Homology Binding Domain in Ovarian Cancer: Expression in Fallopian Tubes and Drug Design.Biomedicines · 2024Article
- Article
- Homologous Recombination Deficiency (HRD) Scoring, by Means of Two Different Shallow Whole-Genome Sequencing Pipelines (sWGS), in Ovarian Cancer Patients: A Comparison with Myriad MyChoice Assay.International journal of molecular sciences · 2023Article
- Article
- UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes:Journal of medical genetics · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Besides
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.